If codeine has never relieved your pain, or works unpredictably, your DNA is probably the reason — and it's not your fault.
June 2026 · 7 min read · Lambert Medical Clinical Team
You've been prescribed codeine for pain. You take it, wait, and feel essentially nothing. Or perhaps it worked well for a while and then seemed to stop. You might have been told to take more, or switched to tramadol, with similarly disappointing results. Before attributing this to high pain tolerance, psychological factors, or some vague "it just doesn't work for me" explanation — consider the possibility that your DNA is the reason.
This surprises many people, including some clinicians. Codeine itself has virtually no pain-relieving activity. It is what pharmacologists call a prodrug — a pharmacologically inactive compound that must be converted into an active substance by the body to have any effect.
The active substance is morphine. The conversion happens in the liver, and it is performed almost entirely by a single enzyme: CYP2D6, part of the cytochrome P450 enzyme family. Without CYP2D6 converting codeine to morphine, no meaningful analgesia occurs — regardless of dose.
The same is true of tramadol, which requires CYP2D6 to convert it to O-desmethyltramadol (its active form), and hydrocodone.
CYP2D6 metabolises approximately 20–25% of all commonly prescribed medications — including codeine, tramadol, many antidepressants, some antipsychotics, and the breast cancer drug tamoxifen. Your inherited CYP2D6 variants determine how active this enzyme is, placing you in one of four metaboliser categories.
~5–10% of the population
Little or no CYP2D6 activity. Codeine produces virtually no morphine. No meaningful pain relief at any standard dose. Often frustrated and labelled as "difficult patients" before the genetic cause is identified.
~5–11% of the population
Reduced CYP2D6 activity. Partial conversion — some pain relief but unpredictable and often subtherapeutic. Higher likelihood of inadequate analgesia.
~56–70% of the population
Standard CYP2D6 activity. Codeine converts to morphine as expected. Standard doses work as the label describes. This is who drug dosing guidelines are written for.
~3–6% (up to 29% in some ethnic groups)
Massively amplified CYP2D6 activity, often due to gene duplication. Codeine converts to morphine at a dangerous rate. Standard doses can cause toxicity — sedation, respiratory depression, or worse.
A 2024 study published in Biomedicine & Pharmacotherapy (Muriel et al.) examined 263 chronic non-cancer pain patients on long-term CYP2D6-related opioids. The findings were striking: patients taking CYP2D6 inhibitor drugs alongside their opioids had significantly higher pain intensity and neuropathic component scores, and significantly lower pain relief — demonstrating in a real clinical population how drug–gene interactions directly impair analgesic outcomes.
The study also highlighted that approximately 34% of patients were taking at least one CYP2D6 substrate drug alongside their opioid, and 24% were taking at least one CYP2D6 inhibitor — without any awareness that this was undermining their pain management.
Even if you are genetically a normal metaboliser, you can be temporarily converted into a poor metaboliser by certain medications you are already taking. This is called phenoconversion.
The most common culprits are widely prescribed antidepressants: paroxetine (Seroxat), fluoxetine (Prozac), bupropion, and duloxetine are all potent CYP2D6 inhibitors. If you are taking one of these alongside codeine or tramadol, the antidepressant may be blocking your CYP2D6 enzyme — making your opioid ineffective even though your DNA says you should be a normal metaboliser.
This is an extremely common clinical scenario. Antidepressants are frequently co-prescribed with pain medications, particularly when chronic pain has a neuropathic component. Yet the interaction is rarely considered at the point of prescribing.
Poor metabolisers face ineffective treatment. But ultrarapid metabolisers face a genuine safety risk. Because they convert codeine to morphine so rapidly, even standard doses can produce morphine levels that cause sedation, nausea, and respiratory depression.
This risk is serious enough that the FDA has contraindicated codeine use in children under 12 — partly because it is impossible to know a child's CYP2D6 type without testing, and the consequences of being an ultrarapid metaboliser at low body weight can be fatal. There have been documented deaths of children given standard post-surgical codeine doses because they were ultrarapid metabolisers.
The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published explicit guidelines recommending that CYP2D6 genotype be considered before prescribing codeine and tramadol. For poor metabolisers, the recommendation is to avoid these drugs entirely and prescribe a non-CYP2D6-dependent opioid (such as morphine, buprenorphine, or oxymorphone) instead. A pharmacogenomics test makes this decision simple, immediate, and evidence-based.
Our pharmacogenomics (PGx) test analyses your CYP2D6 gene variants alongside CYP2C19, CYP2C9, and other pharmacogenes. The result is a comprehensive, CPIC-graded prescribing guide that tells your GP exactly which pain medications are safe, which are unsafe, and which are simply unlikely to work for you — before a single prescription is written.
The test is a cheek swab. No blood draw, no fasting, no preparation. Your DNA doesn't change, so the result is valid for life. Every subsequent prescribing decision — not just for pain, but for antidepressants, cardiovascular drugs, and many others — can be guided by a single test done once.
Full panel covering 50+ medications including codeine, tramadol, antidepressants, tamoxifen, and cardiovascular drugs. Simple cheek swab. Results in 10–14 working days. GP interpretation included.
Find out how your DNA affects codeine, tramadol, antidepressants and 50+ medications. One cheek swab. Lifetime valid.
Book PGx Test Full details